Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04918186 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Study acronym: IPROC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Status, Referencesv25
  2. Primary completion pushed from Jun 30, 2026 to Dec 31, 2026
    • Study sites: 7 to 6
    v24
  3. Site details revised at 6 of 7 sitesv23
  4. Site details revised at 1 of 7 sitesv22
  5. Primary completion date: Jun 30, 2025 to Jun 30, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v21
Show 19 earlier versionsHide 19 earlier versions
  1. Primary completion date: Dec 31, 2024 to Jun 30, 2025
    • Study completion date: Jun 30, 2025 to Dec 31, 2025
    • Interventions: BA3011 (Drug), BA3021 (Drug), Durvalumab (Drug), To be determined (Drug) to BA3011 (Drug), BA3021 (Drug), Durvalumab (Drug), ENB003 (Drug), Toripalimab (Drug)
    v20
  2. Primary completion date: Jun 2024 to Dec 31, 2024
    • Study completion date: Jun 2025 to Jun 30, 2025
    v19
  3. Study sites revised (7)v18
  4. Re-verified, no change to tracked fieldsv17
  5. Study sites revised (7)v16
  6. Site contacts updated at 1 of 7 sitesv15
  7. Start date: Oct 12, 2021 to May 3, 2022v14
  8. Study sites: 6 to 7v13
  9. Study sites: 5 to 6v12
  10. Re-verified, no change to tracked fieldsv11
  11. Study sites: 4 to 5v10
  12. Site details revised at 1 of 4 sitesv9
  13. Study sites: 3 to 4v8
  14. Study sites: 2 to 3v7
  15. Primary endpoint revised
    • Eligibility criteria expanded, about 41 words
    • Secondary endpoints revised (4)
    v6
  16. Study sites: 1 to 2v5
  17. Study Status, Contacts/Locationsv4
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 2021 to Oct 12, 2021
    • Collaborators revised (3)
    v3
  19. Start date: Jun 2021 to Nov 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Trial Details
NCT Number NCT04918186
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Cancer Research Institute, New York City, AstraZeneca, BioAtla, Inc.
Conditions
(from sponsor)		 Ovarian Cancer
Related terms Ovarian Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov